健康对照者和帕金森病患者中使用碘-123-FP-CIT单光子发射计算机断层扫描成像检测多巴胺转运体

Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

作者信息

Booij J, Habraken J B, Bergmans P, Tissingh G, Winogrodzka A, Wolters E C, Janssen A G, Stoof J C, van Royen E A

机构信息

Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.

出版信息

J Nucl Med. 1998 Nov;39(11):1879-84.

PMID:9829575

Abstract

UNLABELLED

Several SPECT studies reported decreased striatal 123I-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodoph enyl)nortropane ([123I]FP-CIT) binding in patients with Parkinson's disease. For application in routine clinical studies, information on the reliability and reproducibility of the [123I]FP-CIT SPECT technique is critical. This study reports on the reliability and reproducibility of [I23I]FP-CIT SPECT in healthy control subjects and patients with Parkinson's disease using two different analysis protocols: the conventional region of interest (ROI) protocol and a newly developed, fully automatic, operator-independent volume of interest (VOI) protocol.

METHODS

We performed repeated [123I]FP-CIT SPECT scans in 6 healthy control subjects and 10 patients with Parkinson's disease to measure scan-to-scan variations. Scintigraphic data were analyzed 3 hr after injection of the radiotracer.

RESULTS

In controls, the mean test/retest for the ratio of the striatal-to-nonspecific [123I]FP-CIT uptake were (3.79 +/- 0.67/3.82 +/- 0.74) and (4.16 +/- 0.70/4.08 +/- 0.97) for the ROI and VOI technique, respectively. No significant differences were measured between test/retest studies. The mean test/retest variability for the ROI technique was low (7.25%) with excellent reliability (rho = 0.99). In addition, the mean test/retest variability for the VOI technique was also low (7.47%) with very high reliability (rho = 0.95). In Parkinson's disease patients, we found mean test/retest for the striatal-to-nonspecific [123I]FP-CIT ratio of (1.78 +/- 0.23/1.79 +/- 0.25) and (1.83 +/- 0.31/1.85 +/- 0.35) using the ROI and VOI technique, respectively. Also in patients, these results did not differ significantly between test/retest studies. The mean test/retest variability for the ROI technique was low (7.90%) with excellent reliability (rho = 1.00). In addition, the mean test/retest variability for the VOI technique was also low (7.36%) with high reliability (rho = 0.96).

CONCLUSION

Reliable and reproducible results were obtained with the ROI, as well as the VOI technique, for the analysis of striatal dopamine transporters with [123I]FP-CIT SPECT in healthy controls and Parkinson's disease patients. The use of an operator-independent method will be a great advantage in routine clinical studies.

摘要

未标注

多项单光子发射计算机断层扫描（SPECT）研究报告称，帕金森病患者纹状体中123I-N-ω-氟丙基-2β-甲氧基羰基-3β-（4-碘苯基）去甲托烷（[123I]FP-CIT）的结合减少。对于常规临床研究的应用而言，[123I]FP-CIT SPECT技术的可靠性和可重复性信息至关重要。本研究报告了使用两种不同分析方案对健康对照者和帕金森病患者进行[123I]FP-CIT SPECT检查的可靠性和可重复性：传统的感兴趣区（ROI）方案和新开发的、完全自动的、与操作者无关的感兴趣体积（VOI）方案。

方法

我们对6名健康对照者和10名帕金森病患者进行了重复的[123I]FP-CIT SPECT扫描，以测量扫描间的差异。在注射放射性示踪剂3小时后对闪烁扫描数据进行分析。

结果

在对照组中，ROI技术和VOI技术的纹状体与非特异性[123I]FP-CIT摄取比值的平均重测值分别为（3.79±0.67/3.82±0.74）和（4.16±0.70/4.08±0.97）。重测研究之间未测得显著差异。ROI技术的平均重测变异性较低（7.25%），可靠性极佳（rho = 0.99）。此外，VOI技术的平均重测变异性也较低（7.47%），可靠性非常高（rho = 0.95）。在帕金森病患者中，使用ROI技术和VOI技术时，纹状体与非特异性[123I]FP-CIT比值的平均重测值分别为（1.78±0.23/1.79±0.25）和（1.83±0.31/1.85±0.35）。同样在患者中，这些结果在重测研究之间也没有显著差异。ROI技术的平均重测变异性较低（7.90%），可靠性极佳（rho = 1.00）。此外，VOI技术的平均重测变异性也较低（7.36%），可靠性较高（rho = 0.96）。